Compare
Cero Therapeutics Holdings, Inc. vs Viskase Holdings, Inc. vs Scilex Holding Co vs Monte Rosa Therapeutics, Inc.
| Latest fiscal year | Cero Therapeutics Holdings, Inc. CERO | Viskase Holdings, Inc. VISKRevenue covers only part of its income (partial revenue) | Scilex Holding Co SCLXRevenue covers only part of its income (partial revenue) | Monte Rosa Therapeutics, Inc. GLUE |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $30.25M | $123.67M |
| Revenue growth (YoY) | n/a | n/a | -46.5% | +63.5% |
| Gross margin | n/a | n/a | 65.0% (computed) | n/a |
| Operating margin | n/a | n/a | n/m | -43.8% |
| Net margin | n/a | n/a | n/m | -31.2% |
| Net income | -$19.92M | -$3.41M | -$374.05M | -$38.63M |
| EPS (Diluted) | n/a | -$0.07 | -$36.48 | n/a |
| Operating cash flow | -$16.10M | -$3.01M | $3.82M | -$22.80M |
| Free cash flow | n/a | n/a | $3.68M | -$27.50M |
| Cash & equivalents | n/a | $42.57M | $4.96M | $129.88M |
| Total assets | $3.64M | $42.81M | $364.98M | $448.66M |
| Total liabilities | $9.09M | n/a | $576.73M | $215.60M |
| Shareholders' equity | -$5.45M | -$2.52M | -$207.78M | $233.06M |
| Return on year-end equity | n/a | n/a | n/a | -16.6% |
| Shares outstanding | n/a | 74.21M | 7.03M | 65.54M |
Revenue, most recent five fiscal years
| Fiscal year | Cero Therapeutics Holdings, Inc. | Viskase Holdings, Inc. | Scilex Holding Co | Monte Rosa Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | n/a | n/a | $123.67M Ended 2025-12-31 |
| 1 year earlier | n/a | n/a | n/a | $75.62M Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | n/a | $0 Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | n/a | n/a |
| 4 years earlier | n/a | n/a | n/a | n/a |